Advertisement
News
Advertisement

Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers

Mon, 06/14/2010 - 5:39am
Bio-Medicine.Org

SUNNYVALE, Calif., June 14 /PRNewswire/ -- The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent® Electronic Brachytherapy, eBx™ System.  The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy (IORT) and accelerated brachytherapy applications.  The most recent publication is four-year data from the TARGIT-A (Targeted Intraoperative Radiation Therapy) multicenter clinical trial presented this week at the 46th Annual ASCO Meeting and published in the current issue of the LANCET.

"We commend the TARGIT researchers and are encouraged that the study continues to reinforce the clinical value of isotope-free electronic treatment for IORT and accelerated brachytherapy applications," said Michael Klein, president and CEO of Xoft. "We are pleased with the growing adoption of IORT for breast and other cancers and we strongly believe that continued research will further prove its ability to improve patient care and similarly catalyze continued adoption."  

The TARGIT-A Trial is a randomized controlled trial designed to assess the equivalency of intraoperative radiotherapy with a single-dose against standard three to six week external beam radiotherapy after breast conserving surgery in women 45 years and over with invasive ductal carcinoma.

Results from the study, "Twelve-Month Follow-Up Results of a Trial Utilizing Xoft Axxent Electronic Brachytherapy to Deliver Intraoperative Radiation Therapy for the Early Stage Breast Cancer," were also presented rece

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading